OAM
JUNO

Oxford Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Oxford Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-43,391
Closed -$1.3M – 933
2016
Q3 		$1.3M Buy
+43,391
New +$1.35M 0.04% 475

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Oxford Asset Management's JUNO Position: Q4 2016 in Review

Oxford Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 43,391 shares — an estimated $1.3M sold.

Oxford Asset Management first reported a position in JUNO in Q3 2016 and held it in 1 quarter. The position peaked at $1.3M in Q3 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

  • Oxford Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Oxford Asset Management sold 43,391 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $1.3M.
  • Oxford Asset Management first reported a position in Juno Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Oxford Asset Management's Juno Therapeutics, Inc. position peaked at $1.3M in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Oxford Asset Management's 13F filing for Q4 2016, filed 9 Feb 2017.